Medicine

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.

A. Cheng, Yoon-Koo Kang, Zhendong Chen, C. Tsao, S. Qin, Jun Suk Kim, R. Luo, Jifeng Feng, S. Ye, Tsai‐Sheng Yang, Jianming Xu, Yan Sun, Houjie Liang, Jiwei Liu, Jie-jun Wang, W. Tak, H. Pan, K. Burock, J. Zou, D. Voliotis, Z. Guan

2009LANCET ONCOLOGY

DOI: 10.1016/s1470-2045(08)70285-7

tlooto Summary

Sorafenib is effective for the treatment of advanced hepatocellular carcinoma in patients from the Asia-Pacific region, and is well tolerated.

Abstract

Abstract is not available.

Citation format

CHENG, A., et al. Efficacy and safety of sorafenib in patients in the asia-pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. LANCET ONCOLOGY, 2009, 10 1: 25–34.